Recent Updates
Recently added Catalysts
NBP Positive Sentiment

NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026

Key Takeaway: NovaBridge Biosciences will hold a webcast on August 20, 2026, to discuss its financial results for the first half of the year and recent corporate developments. The company focuses on innovative therapies in oncology and ophthalmology, with programs like givastomig and VIS-101. The webcast will be accessible live and archived for later viewing.

Market Sentiment Analysis

POSITIVE FACTORS

  • NovaBridge is advancing its therapeutic programs in oncology and ophthalmology.
  • The company is committed to identifying differentiated innovations.
  • A webcast will provide insights into recent corporate progress and financial results.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+46%
120-day peak, hindsight
Typical move
6.6%
average across 3 past catalysts
Lead asset
TJ004309
Phase 2 · Ovarian Cancer

Full Press Release Details

ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that it will hold a webcast on Thursday, August 20, 2026 at 9:00 AM ET/9:00 PM China Standard Time to discuss recent corporate progress and financial results for the first half ended June 30, 2026.

Webcast Information:

• Date: Thursday, August 20, 2026
• Time: 9:00 AM ET/9:00 PM China Standard Time
• Web Access - China: Click here
• Webcast Access – All other locations: Click here
The live and archived webcast can also be accessed by visiting the NovaBridge Biosciences website on the Upcoming Events section of the Investors page. A replay of the webcast will be archived for at least 30 days after the event.

About NovaBridge

NovaBridge Biosciences (Nasdaq: NBP) is a global biotechnology company advancing a portfolio of therapeutic programs in oncology and ophthalmology.. The Company identifies differentiated therapeutic opportunities, generates value-defining clinical evidence, and applies the development, financing, and partnering strategy best suited to each program.
NovaBridge's portfolio includes programs in oncology and ophthalmology, led by givastomig and VIS-101. The Company's objective is to build a sustainable biotechnology company by repeatedly identifying differentiated innovation, advancing it efficiently, and bringing innovative therapies to patients through the path best suited to each opportunity.
For more information, please visit www.novabridge.com and follow us on LinkedIn.

NovaBridge Investor & Media Contacts

Frequently Asked Questions

When will NovaBridge report its financial results?

NovaBridge will report its financial results on August 20, 2026.

What time is the NovaBridge webcast scheduled?

The webcast is scheduled for 9:00 AM ET on August 20, 2026.

What therapeutic areas does NovaBridge focus on?

NovaBridge focuses on oncology and ophthalmology.

How can I access the NovaBridge webcast?

The webcast can be accessed via links provided on the NovaBridge website.

Last updated: Aug 13, 2026